RVNC
Income statement / Annual
Last year (2023), Revance Therapeutics, Inc.'s total revenue was $234.04 M,
an increase of 76.55% from the previous year.
In 2023, Revance Therapeutics, Inc.'s net income was -$323.99 M.
See Revance Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$234.04 M |
$132.57 M |
$77.80 M |
$15.33 M |
$413.00 K |
$3.73 M |
$262.00 K |
$300.00 K |
$300.00 K |
$383.00 K |
| Cost of Revenue |
$152.16 M
|
$51.67 M
|
$23.41 M
|
$4.77 M
|
$102.86 M
|
$92.50 M
|
$0.00
|
$0.00
|
$2.00 M
|
$0.00
|
| Gross Profit |
$81.88 M
|
$80.90 M
|
$54.39 M
|
$10.56 M
|
-$102.45 M
|
-$88.77 M
|
$262.00 K
|
$300.00 K
|
-$1.70 M
|
$383.00 K
|
| Gross Profit Ratio |
0.35
|
0.61
|
0.7
|
0.69
|
-248.06
|
-23.81
|
1
|
1
|
-5.65
|
1
|
| Research and Development Expenses |
$79.41 M
|
$101.29 M
|
$116.26 M
|
$125.80 M
|
$102.86 M
|
$92.50 M
|
$80.36 M
|
$50.38 M
|
$47.53 M
|
$33.39 M
|
| General & Administrative Expenses |
$38.81 M
|
$36.60 M
|
$192.62 M
|
$149.74 M
|
$62.01 M
|
$53.86 M
|
$37.40 M
|
$29.08 M
|
$25.09 M
|
$19.04 M
|
| Selling & Marketing Expenses |
$253.42 M
|
$183.10 M
|
$6.20 M
|
$2.10 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$292.24 M
|
$219.70 M
|
$198.82 M
|
$151.85 M
|
$62.01 M
|
$53.86 M
|
$37.40 M
|
$29.08 M
|
$25.09 M
|
$19.04 M
|
| Other Expenses |
$27.01 M
|
$27.85 M
|
$13.99 M
|
$6.08 M
|
-$303.00 K
|
-$773.00 K
|
-$525.00 K
|
-$535.00 K
|
-$327.00 K
|
-$234.00 K
|
| Operating Expenses |
$398.65 M
|
$353.07 M
|
$329.06 M
|
$283.72 M
|
$164.87 M
|
$146.36 M
|
$117.76 M
|
$79.46 M
|
$72.62 M
|
$52.43 M
|
| Cost And Expenses |
$550.82 M
|
$404.73 M
|
$352.47 M
|
$288.49 M
|
$164.87 M
|
$146.36 M
|
$117.76 M
|
$79.46 M
|
$72.62 M
|
$52.43 M
|
| Interest Income |
$13.29 M
|
$4.89 M
|
$337.00 K
|
$4.32 M
|
$5.53 M
|
$4.02 M
|
$1.41 M
|
$1.17 M
|
$231.00 K
|
$44.00 K
|
| Interest Expense |
$19.36 M
|
$16.47 M
|
$6.27 M
|
$15.15 M
|
$0.00
|
$44.00 K
|
$457.00 K
|
$1.08 M
|
$1.19 M
|
$10.67 M
|
| Depreciation & Amortization |
$13.69 M
|
$33.73 M
|
$19.85 M
|
$10.25 M
|
$2.91 M
|
$1.73 M
|
$1.47 M
|
$1.45 M
|
$2.00 M
|
$2.05 M
|
| EBITDA |
-$290.64 M |
-$305.52 M |
-$255.18 M |
-$259.31 M |
-$156.52 M |
-$137.80 M |
-$118.66 M |
-$86.74 M |
-$70.29 M |
-$50.00 M |
| EBITDA Ratio |
-1.24
|
-2.3
|
-3.28
|
-16.92
|
-378.98
|
-36.95
|
-452.91
|
-289.14
|
-234.3
|
-130.55
|
| Operating Income Ratio |
-1.35
|
-2.05
|
-3.53
|
-17.82
|
-398.21
|
-38.25
|
-459.63
|
-294.05
|
-241.06
|
-135.9
|
| Total Other Income/Expenses Net |
-$6.91 M
|
-$13.76 M
|
-$6.63 M
|
-$11.55 M
|
$5.03 M
|
$3.07 M
|
-$163.00 K
|
-$1.06 M
|
-$1.16 M
|
-$10.87 M
|
| Income Before Tax |
-$323.69 M
|
-$355.72 M
|
-$281.31 M
|
-$284.71 M
|
-$159.43 M
|
-$139.57 M
|
-$120.59 M
|
-$89.27 M
|
-$73.48 M
|
-$62.92 M
|
| Income Before Tax Ratio |
-1.38
|
-2.68
|
-3.62
|
-18.58
|
-386.03
|
-37.43
|
-460.26
|
-297.57
|
-244.92
|
-164.27
|
| Income Tax Expense |
$300.00 K
|
$700.00 K
|
$0.00
|
-$2.62 M
|
$0.00
|
$3.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$323.99 M
|
-$356.42 M
|
-$286.82 M
|
-$282.09 M
|
-$156.22 M
|
-$142.57 M
|
-$120.59 M
|
-$89.27 M
|
-$73.48 M
|
-$62.92 M
|
| Net Income Ratio |
-1.38
|
-2.69
|
-3.69
|
-18.41
|
-378.25
|
-38.23
|
-460.26
|
-297.57
|
-244.92
|
-164.27
|
| EPS |
-3.83 |
-4.9 |
-4.25 |
-4.86 |
-3.59 |
-3.94 |
-4.01 |
-3.18 |
-3.02 |
-3.24 |
| EPS Diluted |
-3.83 |
-4.9 |
-4.25 |
-4.86 |
-3.59 |
-3.94 |
-4.01 |
-3.18 |
-3.02 |
-3.24 |
| Weighted Average Shares Out |
$84.60 M
|
$72.71 M
|
$67.51 M
|
$58.01 M
|
$43.46 M
|
$36.17 M
|
$30.10 M
|
$28.11 M
|
$24.33 M
|
$19.39 M
|
| Weighted Average Shares Out Diluted |
$84.60 M
|
$72.71 M
|
$67.51 M
|
$58.01 M
|
$43.46 M
|
$36.17 M
|
$30.10 M
|
$28.11 M
|
$24.34 M
|
$19.39 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
